NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Investment analysts at William Blair issued their Q1 2023 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Monday, April 3rd. William Blair analyst M. Phipps anticipates that the company will earn ($0.41) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($2.16) per share. William Blair also issued estimates for NewAmsterdam Pharma’s Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.44) EPS, Q4 2023 earnings at ($0.45) EPS, FY2023 earnings at ($1.72) EPS and FY2024 earnings at ($1.14) EPS.
Several other equities analysts have also recently commented on the stock. Credit Suisse Group increased their price target on shares of NewAmsterdam Pharma from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Monday. SVB Leerink began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, December 20th. They issued an “outperform” rating and a $19.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on shares of NewAmsterdam Pharma in a report on Monday, December 19th. They issued a “buy” rating and a $24.00 target price on the stock.
NewAmsterdam Pharma Price Performance
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. acquired a new position in NewAmsterdam Pharma in the fourth quarter worth approximately $101,823,000. RA Capital Management L.P. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $43,600,000. Medicxi Ventures Management Jersey Ltd acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $21,800,000. GMT Capital Corp acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $10,900,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $1,892,000.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
Read More
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Hypercharge Networks: Up Triple Digits, But What’s The Big Deal?
- 3 Reasons Why Apple’s 30% Rally Has Legs
- 3 Reasons to Pick First Citizens Instead of First Republic Bank
- 3 April Earnings Plays for Bullish Swing Traders
- Is Constellation Brands Star About To Rise?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
